Evidence map›Paper›PMID 39202077›Full record

ArticleJournal of personalized medicine2024

Assessing the Impact of IL-6 and Serotonin on Pain and Symptomatology in Fibromyalgia: An Exploratory Clinical Study.

Felipe Altino Loçasso, Hélcio Alvarenga Filho, Regina Maria Papais Alvarenga, Sérgio Luís Schimidt, Filipe Kleinman Fiorelli, Plínio Dos Santos Ramos, Sônia Cristina Leal Leidersnaider, Kenneth Blum, Kai-Uwe Lewandrowski, Edezio Ferreira Cunha-Junior and 1 more

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Felipe Altino LoçassoPrograma de Pós-Graduação em Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro 20270-004, Brazil.ORCID 0009-0009-1005-5930
Hélcio Alvarenga FilhoPrograma de Pós-Graduação em Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro 20270-004, Brazil.
Regina Maria Papais AlvarengaPrograma de Pós-Graduação em Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro 20270-004, Brazil.
Sérgio Luís SchimidtPrograma de Pós-Graduação em Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro 20270-004, Brazil.ORCID 0000-0001-7654-5507
Filipe Kleinman FiorelliFaculdade de Ciências Médicas de Três Rios (SUPREMA), Rio de Janeiro 25804-250, Brazil.
Plínio Dos Santos RamosFaculdade de Ciências Médicas de Três Rios (SUPREMA), Rio de Janeiro 25804-250, Brazil.
Sônia Cristina Leal LeidersnaiderFaculdade de Ciências Médicas de Três Rios (SUPREMA), Rio de Janeiro 25804-250, Brazil.
Kenneth BlumDivision of Addiction Research & Education, Center for Sports, Exercise & Mental Health, Western University, Health Sciences, Pomona, CA 91766, USA.ORCID 0000-0001-6727-803X
Kai-Uwe LewandrowskiCenter for Advanced Spine Care of Southern Arizona, The Surgical Institute of Tucson, 4787 E Camp Lowell Dr., Tucson, AZ 85712, USA.ORCID 0000-0001-7842-2914
Edezio Ferreira Cunha-JuniorInstituto de Ciências Farmacêuticas, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Rio de Janeiro 27930-560, Brazil.ORCID 0000-0002-2833-1771
Rossano Kepler Alvim FiorelliPrograma de Pós-Graduação em Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro 20270-004, Brazil.ORCID 0000-0001-5236-0903

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesFibromyalgia (FM) is a chronic musculoskeletal pain syndrome characterized by widespread pain and a variety of other symptoms, including fatigue, cognitive dysfunction, and sleep disturbances. Recent research has highlighted the potential role of pro-inflammatory cytokines and neurotransmitters in the pathophysiology of FM. This study aimed to investigate the relationship between serum levels of interleukin-6 (IL-6) and serotonin with the clinical parameters observed in patients with fibromyalgia. Additionally, it sought to analyze the similarities and differences among the different groups classified by symptom severity. MATERIALS AND

methodsThis cross-sectional study included 26 female patients aged 20-70 diagnosed with FM according to the American College of Rheumatology (ACR) 2016 criteria and 14 healthy controls (HCs). Serum levels of IL-6 and serotonin were measured using electrochemiluminescence and high-performance liquid chromatography (HPLC), respectively.

resultsFM patients exhibited significantly higher pain scores (VAS), anxiety, and depression levels compared to HCs. FIQ-R scores were significantly elevated in FM patients, with stratification showing 3.8% mild, 65.4% moderate, 23.1% severe, and 7.7% very severe cases. While no significant difference in IL-6 levels was observed between the FM patients and HCs, a trend towards increased IL-6 levels in patients with higher FIQ-R scores was noted. Serum serotonin levels were significantly lower in the FM patients than in the HCs, with moderate patients having lower levels than those classified as severe and very severe.

conclusionsThe study underscores the potential role of IL-6 and serotonin in the pathophysiology of FM, suggesting that these biomarkers could be relevant in assessing the severity and impact of FM. Further research is needed to elucidate these relationships and their implications for developing personalized treatment strategies.

Indexed as

fibromyalgiaFIQ-RIL-6 and serotonin

Identifiers

PMID39202077
PMCPMC11355107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.